BR112017024854A2 - ?composto?. - Google Patents

?composto?.

Info

Publication number
BR112017024854A2
BR112017024854A2 BR112017024854-9A BR112017024854A BR112017024854A2 BR 112017024854 A2 BR112017024854 A2 BR 112017024854A2 BR 112017024854 A BR112017024854 A BR 112017024854A BR 112017024854 A2 BR112017024854 A2 BR 112017024854A2
Authority
BR
Brazil
Prior art keywords
prophylaxis
treatment
organ damage
tetramethylchroman
compounds
Prior art date
Application number
BR112017024854-9A
Other languages
English (en)
Other versions
BR112017024854B1 (pt
Inventor
Cornelis Van Der Graaf Adrianus
Henk Henning Robert
Edwin Deelman Leo
Jan Willem Euverink Gerrit
Original Assignee
Sulfateq B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017024854(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sulfateq B.V. filed Critical Sulfateq B.V.
Publication of BR112017024854A2 publication Critical patent/BR112017024854A2/pt
Publication of BR112017024854B1 publication Critical patent/BR112017024854B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere aos compostos para a profilaxia ou o tratamento de dano em órgão através da restauração da função endotelial e/ou da inibição da produção das espécies de oxigênio reativas e especialmente aos compostos para a profilaxia ou o tratamento do dano renal diabético. especificamente, a presente invenção se refere ao 6-hidroxi-2,5,7,8-tetrametilcroman-2-il)(piperazin-1-il)metanona ou n,6-dihidroxi-2,5,7,8-tetrametilcroman-2-carboxamida ou um sal ou base farmaceuticamente aceitável do mesmo para uso na profilaxia ou no tratamento de dano em órgão através da restauração função endotelial e/ou da inibição da produção das espécies de oxigênio reativas e especialmente o dano ao órgão renal diabético.
BR112017024854-9A 2015-05-22 2016-05-12 Uso de um composto BR112017024854B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2014843 2015-05-22
NL2014843 2015-05-22
PCT/EP2016/060731 WO2016188766A1 (en) 2015-05-22 2016-05-12 Compound for the prophylaxis or treatment of organ damage

Publications (2)

Publication Number Publication Date
BR112017024854A2 true BR112017024854A2 (pt) 2018-08-14
BR112017024854B1 BR112017024854B1 (pt) 2023-12-26

Family

ID=56014996

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024854-9A BR112017024854B1 (pt) 2015-05-22 2016-05-12 Uso de um composto

Country Status (15)

Country Link
US (2) US10676452B2 (pt)
EP (1) EP3297625B1 (pt)
JP (2) JP6967456B2 (pt)
CN (1) CN107660148B (pt)
AU (1) AU2016268975B2 (pt)
BR (1) BR112017024854B1 (pt)
CA (1) CA2986300C (pt)
CL (1) CL2017002960A1 (pt)
DK (1) DK3297625T3 (pt)
ES (1) ES2927699T3 (pt)
HU (1) HUE060167T2 (pt)
MX (1) MX2017014912A (pt)
PL (1) PL3297625T3 (pt)
PT (1) PT3297625T (pt)
WO (1) WO2016188766A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
CA2986300C (en) * 2015-05-22 2024-02-20 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage
EP3672593A1 (en) 2017-08-25 2020-07-01 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
WO2019038360A1 (en) 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
ES2963906T3 (es) * 2017-11-22 2024-04-03 Khondrion Ip B V Compuestos como inhibidores de MPGES-1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681890A (en) 1984-10-30 1987-07-21 Kuraray Co., Ltd. 3,4-dihydrobenzopyran compounds and pharmaceutical composition containing the same
US4728650A (en) 1985-05-13 1988-03-01 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives and medicinal uses thereof
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
US5266709A (en) 1989-03-13 1993-11-30 Ono Pharmaceutical Co., Ltd. Benzopyran derivatives
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6335445B1 (en) * 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
AU2823797A (en) 1997-05-02 1997-11-19 Dr. Reddy's Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
EP1598345A4 (en) 2003-02-26 2006-03-22 Shanghai Inst Materia Medica BENZOPYRANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USES THEREOF
EP1650206A4 (en) 2003-08-01 2006-12-20 Nippon Soda Co PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS
WO2005032544A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
CA2878567C (en) * 2012-07-12 2021-02-23 Khondrion Ip B.V. Chromanyl derivatives for treating mitochondrial disease
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
CA2986300C (en) * 2015-05-22 2024-02-20 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage

Also Published As

Publication number Publication date
CA2986300A1 (en) 2016-12-01
DK3297625T3 (da) 2022-10-17
PL3297625T3 (pl) 2022-11-14
AU2016268975B2 (en) 2021-08-12
BR112017024854B1 (pt) 2023-12-26
EP3297625B1 (en) 2022-07-06
JP2018520106A (ja) 2018-07-26
CN107660148A (zh) 2018-02-02
US20180170892A1 (en) 2018-06-21
CA2986300C (en) 2024-02-20
EP3297625A1 (en) 2018-03-28
HUE060167T2 (hu) 2023-02-28
CL2017002960A1 (es) 2018-03-16
JP6967456B2 (ja) 2021-11-17
AU2016268975A1 (en) 2017-11-30
US20210024485A1 (en) 2021-01-28
WO2016188766A1 (en) 2016-12-01
CN107660148B (zh) 2021-03-09
ES2927699T3 (es) 2022-11-10
JP2021120381A (ja) 2021-08-19
MX2017014912A (es) 2018-06-13
US10676452B2 (en) 2020-06-09
PT3297625T (pt) 2022-09-27

Similar Documents

Publication Publication Date Title
BR112017024854A2 (pt) ?composto?.
BR112018000482A2 (pt) ?composição herbicida, utilização da composição, método para o controle da vegetação indesejada e utilização?
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
GT201400111A (es) Triazolopiridinas sustituidas
BR112016028476A2 (pt) compostos, composição, utilização de um composto, método para o combate dos fungos nocivos e sementes
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
SG10201804026WA (en) Inhibitors of influenza viruses replication
BR112017012846A2 (pt) derivados do amino tiadiazol como inibidores da nadph oxidase.
BR112013002144A2 (pt) compostos para o tratamento e/ou a prevenção de doeças inflamatórias oculares
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
MX2016010451A (es) Benzoxaboroles microbicidamente activos.
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017011980A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
BR112018005742A2 (pt) composição tópica, método para desinfecção de uma superfície, utilização da composição e utilizações de uma composição
CU20130072A7 (es) 1 h-pirazol-5-olato sódico sustituido
PH12019501873A1 (en) Pharmaceutical composition
BR112018011562A2 (pt) novos derivados de fenil

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2016, OBSERVADAS AS CONDICOES LEGAIS